Skip to content

Clinical trials

Urinary Bladder Neoplasms trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Urinary Bladder Neoplasms Country / region: Italy Clear all

132 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20014
20022
20031
20041
20052
20061
20072
20081
20093
20104
20113
20121
20134
20145
20153
20164
20174
201810
201910
202012
202110
20228
20237
20248
202513
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed55
Recruiting29
Active, not recruiting19
Terminated14
Unknown status12
Not yet recruiting3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Merck Sharp & Dohme LLC9
Bristol-Myers Squibb8
European Organisation for Research and Treatment of Cancer - EORTC8
AstraZeneca7
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano7
Hoffmann-La Roche5
Istituto Clinico Humanitas5
Janssen Research & Development, LLC5
Eli Lilly and Company4
Regina Elena Cancer Institute4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Urinary Bladder Neoplasms132
Carcinoma, Transitional Cell27
Non-Muscle Invasive Bladder Neoplasms15
Ovarian Neoplasms13
Lung Neoplasms12
Breast Neoplasms11
Stomach Neoplasms10
Neoplasms9
Pancreatic Neoplasms9
Prostatic Neoplasms9

Trials

Showing 1 to 25 of 132. Each trial links to its page on Pharma Observatory.

32 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.